Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 61 of 5804
-
Flashing lights and tones could stop Alzheimer's before it starts
Prevention Recruiting nowAlzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, there are fewer gamma waves in the brain. Th…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New blood test spots silent liver metastases in pancreatic cancer patients
Diagnosis CompletedEarly liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery. Reliable preoperative detection of such lesions remains an unmet clinica…
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
New hope for hard-to-treat breast cancer: BL-B01D1 takes on chemo
Disease control OngoingThis trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure.
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for glioblastoma: phase 3 trial pits niraparib against standard chemo
Disease control OngoingThe goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main question it aims to answer is: Does niraparib improve overall survival …
Phase: PHASE3 • Sponsor: Ivy Brain Tumor Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill plus chemo aims to beat High-Risk lymphoma
Disease control OngoingThe purpose of this study is to compare the effectiveness and safety of golcadomide in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy vs placebo in combination with R-CHOP chemotherapy in participants with previously u…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New CAR t therapy targets hidden lymphoma cells after initial treatment
Disease control Recruiting nowThis is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the F…
Phase: PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Gene therapy trial aims to restore night vision in rare eye disease
Disease control OngoingThis is a Phase 3 study to Assess the Efficacy, Safety and Tolerability of OCU400 in patients with retinitis pigmentosa (RP) associated with RHO mutations and patients with any other RP associated mutation with a clinical phenotype of RP. This is a multicenter, assessor blinded …
Phase: PHASE3 • Sponsor: Ocugen • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New CAR T-Cell therapy takes aim at tough T-Cell cancers
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, phase 1/2 study of anti-CD5 CAR-T cell therapy in patients with CD5+ relapsed or refractory T-cell malignancies. A bayesian optimal interval (BOIN) 12 design will be used to explore the optimal biological dose (OBD) from startin…
Phase: PHASE1, PHASE2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Clot removal may help even in massive strokes, new trial hopes to prove
Disease control Recruiting nowThe role of endovascular thrombectomy in patients with extra-large ischemic burden is still unclear. The XL STROKE-2 randomized trial is aiming to investigate the efficacy and safety of mechanical thrombectomy in acute extra-large ischemic stroke patients with large vessel occlus…
Phase: NA • Sponsor: Zhongming Qiu • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill combo could delay advanced breast cancer progression
Disease control OngoingThis is a Phase III clinical trial for patients with a specific type of advanced breast cancer that is HER2-negative and has a biomarker called "Homologous Recombination Deficiency (HRD)-positive." The study aims to compare the effectiveness and safety of two treatment strategie…
Phase: PHASE3 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a simple aspirin pill save pregnancies? major trial launches
Prevention Recruiting nowThe goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are: Does this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? D…
Phase: PHASE3 • Sponsor: University of Pennsylvania • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
New hope for lung cancer patients: experimental drug takes on chemo
Disease control OngoingThe purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for advanced prostate cancer: STAMPEDE2 trial tests targeted therapies
Disease control Recruiting nowSTAMPEDE2 is a clinical trial comparing two new treatments with standard of care in people with prostate cancer that has spread to other parts of the body and is responsive to hormone therapy. People from all backgrounds and ethnicities are encouraged to take part and multiple ho…
Phase: PHASE3 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New hope for elderly leukemia patients: experimental combo trial launches
Disease control Recruiting nowA global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with azacitidine in newly diagnosed acute myeloid leukemia who are…
Phase: PHASE3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a new drug stop inherited Alzheimer's in its tracks?
Disease control OngoingThis is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of amyloid removal on age of onset and clinical progressi…
Phase: PHASE3 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to cut chemo and boost survival in leukemia
Disease control Recruiting nowIn recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R)B-ALL. The available data suggest that the advancement of immunotherapy from relapsed/refractory (R/R) field to th…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New immune cocktail aims to outperform standard lung cancer therapy
Disease control OngoingThe goal of this clinical trial is to evaluate the safety and tolerability profile of dostarlimab in combination with belrestotug when compared with pembrolizumab and placebo in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1 high NSCLC.
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug cocktail aims to extend life in tough lung cancer
Disease control Recruiting nowThis is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cance…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug duo aims to slow advanced lung cancer in first-line trial
Disease control OngoingThe aim of the study is to evaluate the efficacy and safety of SKB264 in combination with pembrolizumab as firstline treatment for patients with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for lymphoma patients: drug duo may beat standard chemo
Disease control Recruiting nowThis study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previou…
Phase: PHASE3 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC